^
Association details:
Biomarker:BLM mutation
Cancer:Prostate Cancer
Drug:Lynparza (olaparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients

Published date:
10/25/2022
Excerpt:
The findings revealed that the mutation population of ATR, BLM, and MLH1 appears more sensitive to Olaparib….Furthermore, mutations in ATR, BLM, and MLH1 or the expression of POLR2L, PMS1, FANCE, and other genes significantly influence Olaparib sensitivity, which may be underlying therapeutic targets in the future....Intriguingly, we discovered that the expression of POLR2L, PMS1, FANCE, WRN, and other genes was closely related to Olaparib sensitivity, suggesting that these genes may be underlying therapeutic targets in clinical practice.
DOI:
https://doi.org/10.1177/107327482211294